Videos

Hirva Mamdani, MD, explains the rationale for conducting a safety and efficacy study of durvalumab in patients following multimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma.

Benjamin P. Levy, MD, discusses the evolution of molecular drivers in non–small cell lung cancer over the last few years and which testing should be included in patients.

Rajat Bannerji, MD, PhD, discusses the safety and efficacy results of REGN1979 in the follicular lymphoma cohort enrolled in the phase I study of patients with relapsed/refractory B-Cell non-Hodgkin lymphoma who were previously treated with an anti-CD20 agent.

Suresh S. Ramalingam, MD, discusses how the EGFR tyrosine kinase inhibitor osimertinib compared with other EGFR inhibitors for patients with EGFR-mutant lung cancer.

Antonio Gonzalez Martín, MD, discusses the results from the phase III PRIMA study, which evaluated the PARP inhibitor niraparib versus placebo as a frontline treatment of patients with newly diagnosed ovarian cancer who responded to platinum-based chemotherapy.

Robert C. Doebele, MD, PhD, shares his thoughts on what the next steps are for entrectinib in patients with&nbsp;<em>ROS1</em>-positive non&ndash;small cell lung cancer. In August of 2019, the FDA granted approval to this agent as treatment of patients with metastatic NSCLC who are&nbsp;<em>ROS1</em>-positive.

Elise Chong, MD, discusses the rationale for conducting a 4-year analysis of tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Kevin M. Sullivan, MD, discusses the current treatment options for patients with lung cancer harboring an&nbsp;<em>ALK</em>&nbsp;mutation.

Wasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shares his expert opinion on the importance of the phase III IMbrave150 trial, which evaluated a targeted therapy combination in patients with hepatocellular carcinoma.<br /> &nbsp;

Willemina R. Geurts-Giele, PhD, discusses 2 approaches used to detect the MET exon 14 skipping mutation in patients with non-small cell lung cancer.

Jennifer A. Woymach, MD, provides background information on the AO41702 study, which evaluates targeted therapy ibrutinib or ibrutinib plus rituximab in elderly patients with previously untreated chronic lymphocytic leukemia.<br /> &nbsp;

Nina Shah, MD, discusses the question of whether CAR T-cell therapy is ready for primetime in patients with multiple myeloma.

Shilpa Gupta, MD, explains the rationale for adding androgen receptor therapy to cisplatin- and gemcitabine-based chemotherapy.

Multiple Myeloma

Benjamin Weinberg, MD, discusses novel agents that may impact the treatment landscape for colorectal cancer once made available in the community setting.

Adam Fisch, MD, PhD, a clinical fellow in molecular genetic pathology at the Brigham&rsquo;s Women&rsquo;s Hospital, discusses the key points from a patient case he presented at the 2019 Association for Molecular Pathology Annual Meeting and Expo, in which the patient with acute myeloid leukemia harboring a FLT3-TKD mutation lost the mutation following relapse on gilteritinib.

Multiple Myeloma

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the current treatment options that are approved around the world for patients with advanced melanoma. These treatments include both immunotherapies, such as immune checkpoint inhibitors, and targeted therapies.

Aiwu Ruth He, MD, discusses the current role of immune checkpoint inhibitors in upper gastrointestinal and gastric cancers and which patients are most likely to benefit from the anti&ndash;PD-1 agents.

Neeraj Agarwal, MD, discusses the results from the randomized phase III TITAN trial, which enrolled over 1,000 patients with newly diagnosed metastatic castration-sensitive prostate cancer and randomized them to either androgen deprivation therapy plus the novel androgen receptor inhibitor apalutamide or ADT alone.

Lori Leslie, MD, discusses toxicities and outcomes observed in patients with chronic lymphocytic leukemia treated with acalabrutinib in real-word clinics.